JP2020515649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515649A5 JP2020515649A5 JP2020503374A JP2020503374A JP2020515649A5 JP 2020515649 A5 JP2020515649 A5 JP 2020515649A5 JP 2020503374 A JP2020503374 A JP 2020503374A JP 2020503374 A JP2020503374 A JP 2020503374A JP 2020515649 A5 JP2020515649 A5 JP 2020515649A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- agent
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024207994A JP2025027084A (ja) | 2017-03-28 | 2024-11-29 | がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1704910.7 | 2017-03-28 | ||
| GBGB1704910.7A GB201704910D0 (en) | 2017-03-28 | 2017-03-28 | High dose combi I |
| GB1718806.1 | 2017-11-14 | ||
| GBGB1718806.1A GB201718806D0 (en) | 2017-11-14 | 2017-11-14 | Breast cancer treatment |
| PCT/GB2018/050843 WO2018178690A1 (en) | 2017-03-28 | 2018-03-28 | An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024207994A Division JP2025027084A (ja) | 2017-03-28 | 2024-11-29 | がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515649A JP2020515649A (ja) | 2020-05-28 |
| JP2020515649A5 true JP2020515649A5 (https=) | 2021-04-30 |
| JP7657590B2 JP7657590B2 (ja) | 2025-04-07 |
Family
ID=61952738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503374A Active JP7657590B2 (ja) | 2017-03-28 | 2018-03-28 | がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 |
| JP2024207994A Pending JP2025027084A (ja) | 2017-03-28 | 2024-11-29 | がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024207994A Pending JP2025027084A (ja) | 2017-03-28 | 2024-11-29 | がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3600433B1 (https=) |
| JP (2) | JP7657590B2 (https=) |
| KR (2) | KR20200072445A (https=) |
| CN (1) | CN111050801B (https=) |
| AU (1) | AU2018244806B2 (https=) |
| CA (1) | CA3083850A1 (https=) |
| ES (1) | ES2897790T3 (https=) |
| WO (1) | WO2018178690A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010049375A1 (en) | 2000-03-15 | 2001-12-06 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
| US20030144312A1 (en) | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
| EP1479381A1 (en) * | 2003-05-19 | 2004-11-24 | Euro-Celtique S.A. | Pharmaceutical dosage form comprising a solid solution |
| EP1868593A2 (en) | 2005-04-07 | 2007-12-26 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
| SMT202500474T1 (it) * | 2010-12-03 | 2026-01-12 | Nalpropion Pharmaceuticals Llc | Aumento della biodisponibilità farmacologica nella terapia con naltrexone |
| JP2015107918A (ja) | 2012-02-14 | 2015-06-11 | 国立研究開発法人国立がん研究センター | 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法 |
| GB201308440D0 (en) * | 2013-05-10 | 2013-06-19 | Dalgleish Angus | Therapeutic |
| WO2016061531A1 (en) * | 2014-10-17 | 2016-04-21 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progression |
-
2018
- 2018-03-28 AU AU2018244806A patent/AU2018244806B2/en active Active
- 2018-03-28 KR KR1020197031888A patent/KR20200072445A/ko not_active Ceased
- 2018-03-28 CN CN201880035530.6A patent/CN111050801B/zh active Active
- 2018-03-28 CA CA3083850A patent/CA3083850A1/en active Pending
- 2018-03-28 ES ES18717108T patent/ES2897790T3/es active Active
- 2018-03-28 KR KR1020247026962A patent/KR20240125082A/ko active Pending
- 2018-03-28 EP EP18717108.7A patent/EP3600433B1/en active Active
- 2018-03-28 WO PCT/GB2018/050843 patent/WO2018178690A1/en not_active Ceased
- 2018-03-28 JP JP2020503374A patent/JP7657590B2/ja active Active
-
2024
- 2024-11-29 JP JP2024207994A patent/JP2025027084A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102612365B (zh) | 用于强化dna损伤剂的检查点激酶1抑制剂 | |
| AU2012321110B2 (en) | Combination treatment | |
| JP2011173928A5 (https=) | ||
| JP2009539769A5 (https=) | ||
| JP2012180381A5 (https=) | ||
| ME02946B (me) | Dimer buprenorfina i njegova upotreba u lecenju gastrointestinalnih poremecaja | |
| JP2021510725A5 (https=) | ||
| JP2021512149A5 (https=) | ||
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| CN108025076A (zh) | 使用阿吡莫德治疗癌症的方法 | |
| JP2016515586A5 (https=) | ||
| JP2017507151A5 (https=) | ||
| JP2017503014A5 (https=) | ||
| JP2016509030A5 (https=) | ||
| Wang et al. | Homoharringtonine: mechanisms, clinical applications and research progress | |
| CN113082039B (zh) | 一种用于治疗索拉菲尼耐药肿瘤的组合物及其应用 | |
| JP2014504636A5 (https=) | ||
| JP2021505669A5 (https=) | ||
| CN101610776A (zh) | 包含CNDAC(2′-氰基-2′-脱氧-N4 -棕榈酰基-1-β-D-阿拉伯呋喃糖基-胞嘧啶)和细胞毒剂的组合 | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JP2018506533A5 (https=) | ||
| JP2017527551A5 (https=) | ||
| US10213436B2 (en) | Methods of treating cancer using aurora kinase inhibitors | |
| CN1615136A (zh) | 包含埃坡霉素和抗代谢物的组合 | |
| CN117797149A (zh) | 西达本胺联合r-chop的应用及联合药物 |